U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07143279) titled 'Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life' on July 03.
Brief Summary: This is a monocentric, single-arm prospective pilot study that will enrol hypogonadal (testosterone < 231 ng/dL) male subjects in best supportive care, with no further therapeutic options and no need for resuscitation.
Currently, testosterone formulations for intramuscular (IM) injection and subcutaneous injection as well as for oral and transdermal administration have been approved for androgen therapy. To date, injectable testosterone is the most commonly used formulation. To increase serum testosterone levels t...